Novartis AG (LON:0QLR)

Market Cap	169.75B
Revenue (ttm)	40.28B
Net Income (ttm)	9.97B
Shares Out	n/a
EPS (ttm)	5.00
PE Ratio	17.03
Forward PE	13.61
Dividend	3.07 (3.28%)
Ex-Dividend Date	Mar 11, 2025

Volume	519,371
Average Volume	306,157
Open	95.48
Previous Close	95.02
Day's Range	93.88 - 95.91
52-Week Range	81.22 - 115.98
Beta	0.53
RSI	49.83
Earnings Date	Jul 17, 2025

About Accolade

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QLR

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.